Korea's 9 Bioclusters: Engines of Biopharma Growth Potential

South Korea has swiftly risen to prominence in the global biopharmaceutical arena, evolving from a manufacturer of generic drugs into an innovative leader in therapeutic development—particularly in the fields of cell and gene therapy and biosimilars. This transformation creates significant opportunities for international companies at the forefront of biopharma innovation.

Index:

• South Korea’s Biopharma Market: A Closer Look
• Strategic Government Initiatives Driving Growth
• Bio-Clusters: Catalysts for Startup Innovation
• Leading Companies Powering Korea’s Global Biopharma Influence
• Market Gaps and Opportunities for Global Collaboration

Download the e-Book HERE
‍

References:

Korea Drug Development Fund. (n.d.). Pipeline data and therapeutic focus.
‍Korea Bioindustry Information Service. (n.d.). Industry statistics on Korean biotech companies.
‍PR Newswire. (2024, April 15). ABL Bio announces Grabody-B brain delivery platform license agreement with GSK to develop novel medicines for neurodegenerative diseases.
‍ABL Bio. (2024). Company news and clinical updates on CTX-009 (ABL001).
‍Korea Ministry of Food and Drug Safety. (n.d.). Approved cell and gene therapies in Korea.
‍Samsung Bioepis. (n.d.). Biosimilar portfolio and financial reports.
‍Celltrion. (n.d.). Company overview and biosimilar achievements.
‍Samsung Biologics. (2024). Manufacturing capacity updates and contract orders.
‍Yuhan Corporation. (n.d.). Global partnerships and Lazertinib development.
‍Orum Therapeutics. (n.d.). Global deals and platform technology overview.
‍Ligachem Biosciences. (n.d.). Antibody-drug conjugate platform and awards.
‍Alteogen. (n.d.). ALT-B4 platform and company history.
‍Korea Ministry of Trade, Industry and Energy (MOTIE). (n.d.). Investment data and industrial policy reports.
‍ClinicalTrials.gov. (2023). Korea’s clinical trials activity ranking and statistics.
‍Intralink Group. (2025, February). South Korea: a new global hub for biopharma.